Travere Therapeutics (TVTX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

TVTX Stock Forecast

Travere Therapeutics stock forecast is as follows: an average price target of $21.75 (represents a 19.11% upside from TVTX’s last price of $18.26) and a rating consensus of 'Buy', based on 15 wall street analysts offering a 1-year stock forecast.

TVTX Price Target

The average price target for Travere Therapeutics (TVTX) is $21.75 based on 1-year price targets from 15 Wall Street analysts in the past 3 months, with a price target range of $33.00 to $12.00. This represents a potential 19.11% upside from TVTX's last price of $18.26.

TVTX Analyst Ratings

Buy

According to 15 Wall Street analysts, Travere Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TVTX stock is 0 'Strong Buy' (0.00%), 12 'Buy' (80.00%), 3 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Travere Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 31, 2024	Liisa Bayko	Evercore ISI	$33.00	$17.50	88.57%	80.72%
Oct 21, 2024	Mohit Bansal	Wells Fargo	$27.00	$17.87	51.09%	47.86%
Oct 10, 2024	Liisa Bayko	Evercore ISI	$30.00	$18.07	66.02%	64.29%
Oct 09, 2024	Jason Zemansky	Bank of America Securities	$20.00	$15.21	31.49%	9.53%
Oct 01, 2024	Carter Gould	Barclays	$18.00	$13.99	28.66%	-1.42%
Sep 27, 2024	Vamil Divan	Guggenheim	$23.00	$15.04	52.93%	25.96%
Sep 27, 2024	Ed Arce	H.C. Wainwright	$18.00	$15.04	19.68%	-1.42%
Sep 27, 2024	Greg Harrison	Bank of America Securities	$18.00	$14.01	28.48%	-1.42%
Sep 10, 2024	Ed Nash	Canaccord Genuity	$23.00	$12.70	81.17%	25.96%
Sep 09, 2024	Vamil Divan	Guggenheim	$25.00	$12.62	98.18%	36.91%

Row per page

Go to

The latest Travere Therapeutics stock forecast, released on Oct 31, 2024 by Liisa Bayko from Evercore ISI, set a price target of $33.00, which represents a 88.57% increase from the stock price at the time of the forecast ($17.50), and a 80.72% increase from TVTX last price ($18.26).

Travere Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	1	11	14
Avg Price Target	$33.00	$22.45	$21.71
Last Closing Price	$18.26	$18.26	$18.26
Upside/Downside	80.72%	22.95%	18.89%

In the current month, the average price target of Travere Therapeutics stock is $33.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 80.72% increase as opposed to Travere Therapeutics's last price of $18.26. This month's average price target is up 46.99% compared to last quarter, and up 52.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 29, 2024	Cowen & Co.	Buy	Buy	Hold
Oct 21, 2024	Wells Fargo	Sector Outperform	Sector Outperform	Hold
Oct 21, 2024	Wells Fargo	Buy	Overweight	Upgrade
Oct 16, 2024	Wedbush	Sector Outperform	Sector Outperform	Hold
Oct 16, 2024	Scotiabank	-	Outperform	Initialise
Oct 10, 2024	Evercore ISI	Outperform	Outperform	Hold
Oct 09, 2024	Wedbush	Outperform	Outperform	Hold
Oct 01, 2024	Barclays	Overweight	Overweight	Hold
Sep 27, 2024	Leerink Partners	-	Market Perform	Downgrade
Sep 27, 2024	Stephens	Overweight	Overweight	Hold

Row per page

Go to

Travere Therapeutics's last stock rating was published by Cowen & Co. on Oct 29, 2024. The company gave TVTX a "Buy" rating, the same as its previous rate.

Travere Therapeutics Financial Forecast

Travere Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
Revenue	-	-	-	-	-	-	-	-	-	$37.09M	$59.70M	$56.99M	$55.87M	$53.50M	$54.17M	$48.49M	$57.25M	$68.22M	$54.62M	$47.41M	$50.98M	$51.14M	$48.43M	$47.77M	$46.69M	$44.37M	$44.71M	$39.57M
Avg Forecast	$113.41M	$93.55M	$87.10M	$71.72M	$70.45M	$60.87M	$50.40M	$43.46M	$41.69M	$57.33M	$53.56M	$50.61M	$53.01M	$54.12M	$49.63M	$52.19M	$57.80M	$60.93M	$50.33M	$50.09M	$51.66M	$47.84M	$47.59M	$43.43M	$46.02M	$45.29M	$43.01M	$41.41M
High Forecast	$147.31M	$121.51M	$113.13M	$101.06M	$83.76M	$60.95M	$50.40M	$43.46M	$44.27M	$131.96M	$69.57M	$65.74M	$68.86M	$54.12M	$49.63M	$52.19M	$57.80M	$60.93M	$50.33M	$50.09M	$51.66M	$47.84M	$47.59M	$43.43M	$46.02M	$45.29M	$43.01M	$41.41M
Low Forecast	$91.20M	$75.23M	$70.04M	$50.48M	$64.18M	$60.78M	$50.40M	$43.46M	$39.31M	$15.17M	$43.07M	$40.70M	$42.63M	$54.12M	$49.63M	$52.19M	$57.80M	$60.93M	$50.33M	$50.09M	$51.66M	$47.84M	$47.59M	$43.43M	$46.02M	$45.29M	$43.01M	$41.41M
# Analysts	3	3	3	5	10	9	5	4	8	13	6	6	5	5	5	11	12	11	10	9	9	8	7	6	5	5	5	5
Surprise %	-	-	-	-	-	-	-	-	-	0.65%	1.11%	1.13%	1.05%	0.99%	1.09%	0.93%	0.99%	1.12%	1.09%	0.95%	0.99%	1.07%	1.02%	1.10%	1.01%	0.98%	1.04%	0.96%

Travere Therapeutics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $41.69M, with a low forecast of $39.31M, and a high forecast of $44.27M. TVTX's average Quarter revenue forecast represents a 12.39% increase compared to the company's last Quarter revenue of $37.09M (Sep 23).

Travere Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	3	3	3	5	10	9	5	4	8	13	6	6	5	5	5	11	12	11	10	9	9	8	7	6	5	5	5	5
EBITDA	-	-	-	-	-	-	-	-	-	$-89.24M	$-85.69M	$-67.01M	$-65.03M	$-54.86M	$-50.99M	$-49.65M	$-42.15M	$-8.96M	$-25.98M	$-33.57M	$-17.36M	$-6.24M	$-11.23M	$-7.63M	$-11.11M	$-12.09M	$-25.62M	$-20.14M
Avg Forecast	$-94.31M	$-77.79M	$-72.43M	$-59.64M	$-58.58M	$-50.62M	$-41.91M	$-51.39M	$-34.67M	$-47.68M	$-44.54M	$-46.72M	$-34.03M	$-36.24M	$-33.24M	$-42.47M	$-38.71M	$-40.81M	$-33.71M	$-21.40M	$-34.60M	$-32.04M	$-31.87M	$-29.08M	$-30.82M	$-30.33M	$-28.80M	$-27.73M
High Forecast	$-75.84M	$-62.56M	$-58.24M	$-41.97M	$-53.37M	$-50.55M	$-41.91M	$-41.11M	$-32.69M	$-12.61M	$-35.82M	$-37.38M	$-27.22M	$-36.24M	$-33.24M	$-33.98M	$-38.71M	$-40.81M	$-33.71M	$-17.12M	$-34.60M	$-32.04M	$-31.87M	$-29.08M	$-30.82M	$-30.33M	$-28.80M	$-27.73M
Low Forecast	$-122.50M	$-101.05M	$-94.08M	$-84.04M	$-69.65M	$-50.69M	$-41.91M	$-61.67M	$-36.81M	$-109.74M	$-57.85M	$-56.06M	$-40.83M	$-36.24M	$-33.24M	$-50.97M	$-38.71M	$-40.81M	$-33.71M	$-25.68M	$-34.60M	$-32.04M	$-31.87M	$-29.08M	$-30.82M	$-30.33M	$-28.80M	$-27.73M
Surprise %	-	-	-	-	-	-	-	-	-	1.87%	1.92%	1.43%	1.91%	1.51%	1.53%	1.17%	1.09%	0.22%	0.77%	1.57%	0.50%	0.19%	0.35%	0.26%	0.36%	0.40%	0.89%	0.73%

undefined analysts predict TVTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Travere Therapeutics's previous annual EBITDA (undefined) of $NaN.

Travere Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	3	3	3	5	10	9	5	4	8	13	6	6	5	5	5	11	12	11	10	9	9	8	7	6	5	5	5	5
Net Income	-	-	-	-	-	-	-	-	-	$150.74M	$-85.63M	$-86.33M	$-65.82M	$-69.66M	$-67.03M	$-75.97M	$-51.57M	$-35.64M	$-39.01M	$-53.87M	$-121.62M	$-22.55M	$-26.07M	$808.00K	$-30.26M	$-36.49M	$-38.70M	$-40.98M
Avg Forecast	$5.91M	$-15.71M	$-20.84M	$-33.91M	$-49.39M	$-52.04M	$-61.52M	$-59.48M	$-90.04M	$-82.79M	$-84.67M	$-54.07M	$-43.38M	$-73.45M	$-72.76M	$-49.16M	$-57.02M	$-43.53M	$-52.96M	$-27.35M	$-33.33M	$-39.97M	$-35.65M	$-43.56M	$-45.61M	$-58.79M	$-38.86M	$-35.46M
High Forecast	$8.21M	$-11.71M	$-15.54M	$-10.55M	$-39.67M	$-38.80M	$-45.86M	$-47.58M	$-60.26M	$2.77B	$-63.12M	$-43.26M	$-34.71M	$-73.45M	$-72.76M	$-39.33M	$-57.02M	$-43.53M	$-52.96M	$-21.88M	$-33.33M	$-39.97M	$-35.65M	$-43.56M	$-45.61M	$-58.79M	$-38.86M	$-35.46M
Low Forecast	$4.41M	$-21.82M	$-28.94M	$-43.71M	$-62.34M	$-72.27M	$-85.43M	$-71.38M	$-109.89M	$-2.24B	$-117.57M	$-64.89M	$-52.06M	$-73.45M	$-72.76M	$-58.99M	$-57.02M	$-43.53M	$-52.96M	$-32.82M	$-33.33M	$-39.97M	$-35.65M	$-43.56M	$-45.61M	$-58.79M	$-38.86M	$-35.46M
Surprise %	-	-	-	-	-	-	-	-	-	-1.82%	1.01%	1.60%	1.52%	0.95%	0.92%	1.55%	0.90%	0.82%	0.74%	1.97%	3.65%	0.56%	0.73%	-0.02%	0.66%	0.62%	1.00%	1.16%

Travere Therapeutics's average Quarter net income forecast for Dec 23 is $-90.04M, with a range of $-109.89M to $-60.26M. TVTX's average Quarter net income forecast represents a -159.73% decrease compared to the company's last Quarter net income of $150.74M (Sep 23).

Travere Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	3	3	3	5	10	9	5	4	8	13	6	6	5	5	5	11	12	11	10	9	9	8	7	6	5	5	5	5
SG&A	-	-	-	-	-	-	-	-	-	$67.80M	$74.04M	$72.25M	$62.92M	$57.52M	$52.98M	$46.79M	$42.08M	$36.06M	$34.97M	$36.78M	$35.74M	$31.95M	$34.97M	$33.14M	$27.53M	$29.78M	$38.97M	$32.67M
Avg Forecast	$112.19M	$92.54M	$86.15M	$70.95M	$69.69M	$60.21M	$49.85M	$36.63M	$41.24M	$56.71M	$52.98M	$33.30M	$35.39M	$50.73M	$46.52M	$30.27M	$54.18M	$57.11M	$47.18M	$18.67M	$48.42M	$44.84M	$44.61M	$40.70M	$43.14M	$42.45M	$40.31M	$38.81M
High Forecast	$145.72M	$120.20M	$111.91M	$99.97M	$82.85M	$60.29M	$49.85M	$43.96M	$43.79M	$130.53M	$68.82M	$39.96M	$42.47M	$50.73M	$46.52M	$36.33M	$54.18M	$57.11M	$47.18M	$22.41M	$48.42M	$44.84M	$44.61M	$40.70M	$43.14M	$42.45M	$40.31M	$38.81M
Low Forecast	$90.22M	$74.42M	$69.28M	$49.93M	$63.49M	$60.13M	$49.85M	$29.31M	$38.88M	$15.00M	$42.61M	$26.64M	$28.31M	$50.73M	$46.52M	$24.22M	$54.18M	$57.11M	$47.18M	$14.94M	$48.42M	$44.84M	$44.61M	$40.70M	$43.14M	$42.45M	$40.31M	$38.81M
Surprise %	-	-	-	-	-	-	-	-	-	1.20%	1.40%	2.17%	1.78%	1.13%	1.14%	1.55%	0.78%	0.63%	0.74%	1.97%	0.74%	0.71%	0.78%	0.81%	0.64%	0.70%	0.97%	0.84%

Travere Therapeutics's average Quarter SG&A projection for Dec 23 is $41.24M, based on 8 Wall Street analysts, with a range of $38.88M to $43.79M. The forecast indicates a -39.17% fall compared to TVTX last annual SG&A of $67.80M (Sep 23).

Travere Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	3	3	3	5	10	9	5	4	8	13	6	6	5	5	5	11	12	11	10	9	9	8	7	6	5	5	5	5
EPS	-	-	-	-	-	-	-	-	-	$1.98	$-0.00	$-1.27	$-1.03	$-1.09	$-1.05	$-1.20	$-0.84	$-0.59	$-0.64	$-0.96	$-2.37	$-0.44	$-0.58	$0.02	$-0.70	$-0.85	$-0.92	$-0.99
Avg Forecast	$0.08	$-0.20	$-0.27	$-0.44	$-0.63	$-0.67	$-0.79	$-0.96	$-1.16	$-1.06	$-1.09	$-1.20	$-1.13	$-0.95	$-0.94	$-0.87	$-0.74	$-0.56	$-0.68	$-0.52	$-0.43	$-0.52	$-0.46	$-0.56	$-0.59	$-0.76	$-0.50	$-0.46
High Forecast	$0.11	$-0.15	$-0.20	$-0.14	$-0.51	$-0.50	$-0.59	$-0.71	$-0.77	$35.55	$-0.81	$-0.90	$-0.85	$-0.95	$-0.94	$-0.87	$-0.74	$-0.56	$-0.68	$-0.52	$-0.43	$-0.52	$-0.46	$-0.56	$-0.59	$-0.76	$-0.50	$-0.46
Low Forecast	$0.06	$-0.28	$-0.37	$-0.56	$-0.80	$-0.93	$-1.10	$-1.33	$-1.41	$-28.74	$-1.51	$-1.67	$-1.57	$-0.95	$-0.94	$-0.87	$-0.74	$-0.56	$-0.68	$-0.52	$-0.43	$-0.52	$-0.46	$-0.56	$-0.59	$-0.76	$-0.50	$-0.46
Surprise %	-	-	-	-	-	-	-	-	-	-1.86%	0.00%	1.06%	0.91%	1.15%	1.12%	1.38%	1.14%	1.05%	0.94%	1.84%	5.51%	0.85%	1.26%	-0.04%	1.19%	1.12%	1.83%	2.16%

According to 8 Wall Street analysts, Travere Therapeutics's projected average Quarter EPS for Dec 23 is $-1.16, with a low estimate of $-1.41 and a high estimate of $-0.77. This represents a -158.47% decrease compared to TVTX previous annual EPS of $1.98 (Sep 23).

Travere Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VTYX	Ventyx Biosciences	$1.73	$33.86	1857.23%	Buy
GPCR	Structure Therapeutics	$30.10	$92.40	206.98%	Buy
FIXX	Q32 Bio	$0.93	$2.70	190.32%	Buy
STOK	Stoke Therapeutics	$11.27	$30.60	171.52%	Buy
APLS	Apellis Pharmaceuticals	$27.75	$74.50	168.47%	Buy
ANAB	AnaptysBio	$21.17	$52.00	145.63%	Buy
COGT	Cogent Biosciences	$8.98	$18.83	109.69%	Buy
LEGN	Legend Biotech	$39.75	$82.69	108.03%	Buy
KROS	Keros Therapeutics	$53.84	$102.60	90.56%	Buy
IDYA	IDEAYA Biosciences	$26.60	$46.58	75.11%	Buy
CYTK	Cytokinetics	$47.67	$83.23	74.60%	Buy
MGTX	MeiraGTx	$5.92	$9.00	52.03%	Buy
AKRO	Akero Therapeutics	$31.20	$46.00	47.44%	Buy
PCVX	Vaxcyte	$88.39	$124.00	40.29%	Buy
RNA	Avidity Biosciences	$42.56	$54.50	28.05%	Buy
DICE	DICE Therapeutics	$47.55	$60.00	26.18%	Buy
NUVL	Nuvalent	$92.73	$111.57	20.32%	Buy
PTGX	Protagonist Therapeutics	$41.65	$50.00	20.05%	Buy
TVTX	Travere Therapeutics	$18.26	$21.75	19.11%	Buy
RVMD	Revolution Medicines, Inc. Warrant	$56.78	$60.63	6.78%	Buy
CERE	Cerevel Therapeutics	$44.96	$33.50	-25.49%	Buy

TVTX Forecast FAQ

Is Travere Therapeutics a good buy?

Yes, according to 15 Wall Street analysts, Travere Therapeutics (TVTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 80.00% of TVTX's total ratings.

What is TVTX's price target?

Travere Therapeutics (TVTX) average price target is $21.75 with a range of $12 to $33, implying a 19.11% from its last price of $18.26. The data is based on 15 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Travere Therapeutics stock go up soon?

According to Wall Street analysts' prediction for TVTX stock, the company can go up by 19.11% (from the last price of $18.26 to the average price target of $21.75), up by 80.72% based on the highest stock price target, and down by -34.28% based on the lowest stock price target.

Can Travere Therapeutics stock reach $30?

TVTX's highest twelve months analyst stock price target of $33 supports the claim that Travere Therapeutics can reach $30 in the near future.

What is Travere Therapeutics's current price target trend?

1 Wall Street analyst forecast a $33 price target for Travere Therapeutics (TVTX) this month, up 80.72% from its last price of $18.26. Compared to the last 3 and 12 months, the average price target increased by 22.95% and increased by 18.89%, respectively.

What are Travere Therapeutics's analysts' financial forecasts?

Travere Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $225.17M (high $238.57M, low $218.82M), average EBITDA is $-202M (high $-187M, low $-224M), average net income is $-222M (high $-172M, low $-291M), average SG&A $216.38M (high $236.96M, low $202.77M), and average EPS is $-3.054 (high $-2.313, low $-4.16). TVTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $365.78M (high $483.01M, low $286.95M), average EBITDA is $-304M (high $-239M, low $-402M), average net income is $-64.557M (high $-29.593M, low $-90.064M), average SG&A $361.83M (high $477.79M, low $283.85M), and average EPS is $-0.83 (high $-0.38, low $-1.158).

Did the TVTX's actual financial results beat the analysts' financial forecasts?

Based on Travere Therapeutics's last annual report (Dec 2022), the company's revenue was $212.02M, beating the average analysts forecast of $208.96M by 1.47%. Apple's EBITDA was $-244M, beating the average prediction of $-146M by 67.36%. The company's net income was $-278M, beating the average estimation of $-239M by 16.64%. Apple's SG&A was $220.21M, beating the average forecast of $162.91M by 35.17%. Lastly, the company's EPS was $-4.37, beating the average prediction of $-3.891 by 12.32%. In terms of the last quarterly report (Sep 2023), Travere Therapeutics's revenue was $37.1M, missing the average analysts' forecast of $57.33M by -35.30%. The company's EBITDA was $-89.241M, beating the average prediction of $-47.678M by 87.17%. Travere Therapeutics's net income was $150.74M, missing the average estimation of $-82.791M by -282.07%. The company's SG&A was $67.8M, beating the average forecast of $56.71M by 19.55%. Lastly, the company's EPS was $1.98, missing the average prediction of $-1.064 by -286.01%